China-based Suzhou Ribo Life Science Co Ltd (HK:06938) and Sweden-based Ribocure Pharmaceuticals AB (together 'Ribo') announced on Wednesday the submission of a Phase 2 clinical trial application to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease.
Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established an anticoagulation/antithrombotic pipeline.
This new submission for coronary artery disease represents a key milestone in Ribo's programme to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases.
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
Eli Lilly reports positive Phase 1b results for VERVE-102
Dicot Pharma submits FDA application for LIB-01 phase 2b study
European Commission approves Pharming's Joenja for APDS treatment in the EU
Caliway Biopharmaceuticals receives US FDA IND clearance for second global Phase 3 study of CBL-514
AbbVie's MAVIRET receives positive opinion from European regulator
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment